MedPath

Brevera™ Breast Biopsy System Data Collection Study

Completed
Conditions
Breast Cancer Female
Interventions
Device: Brevera Breast Biopsy System
Registration Number
NCT03456583
Lead Sponsor
Hologic, Inc.
Brief Summary

The Brevera Breast Biopsy System integrates tissue acquisition, real time imaging, and post biopsy handling all during the same procedure. This post-market clinical trial will be performed to obtain clinical/operational data and feedback on the Brevera Breast Biopsy System.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
500
Inclusion Criteria
  • Female aged 18 years of age or older
  • Subject has at least one breast imaging finding requiring biopsy for which images are available
  • Subject is able to understand, read and sign the trial specific informed consent form after the nature of the trial has been fully explained to her
Exclusion Criteria
  • Patients who, based on the physician's judgment, may be at increased risk or develop complications associated with core removal or biopsy.
  • Patients receiving anticoagulant therapy or may have bleeding disorders which may put the patient at increased risk of procedural complications based upon physicians judgment.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Brevera Breast Biopsy SystemBrevera Breast Biopsy SystemThe Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
Primary Outcome Measures
NameTimeMethod
Procedural TimeThrough study completion, enrollment expected to take up to 6-10 months at each site - Data collected from day of Breast Biopsy Procedure Only

Total time elapsed between from when the subject enters the procedure room until she has left the procedure room.

Secondary Outcome Measures
NameTimeMethod
Post-biopsy Complication RatesThrough study completion, enrollment expected to take up to 6-10 months at each site - Data collected from day of Breast Biopsy Procedure Only

Adverse event rates.

Average Number of Cores Per LesionThrough study completion, enrollment expected to take up to 6-10 months at each site - Data collected from day of Breast Biopsy Procedure Only

The average number of cores obtained for each lesion across all sites.

Percentage of Procedures With Overall Positive Opinion From Radiologist, Technologist, and PatientThrough study completion, enrollment expected to take up to 6-10 months at each site - Data collected from day of Breast Biopsy Procedure Only

The radiologists, technologists, and patients participating in this study were asked to provide feedback on the Brevera Biopsy System at the completion of each procedure. Their responses (raw scores) were reported and converted to percentage of procedures with overall positive opinions. The scale goes from 0% (poor/negative opinion) to 100% (excellent/positive opinion).

Trial Locations

Locations (6)

Institut régional du Cancer de Montpellier

🇫🇷

Montpellier, France

Radiologia Senologica

🇮🇹

Milan, Italy

Noordwest Ziekenhuisgroep

🇳🇱

Alkmaar, Netherlands

Royal Free Londan NHS Foundation Trust

🇬🇧

London, United Kingdom

Brustdiagnostik Munchen

🇩🇪

Tübingen, Germany

Centro de Patalogia de la Mama-Fundacion Tejerina

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath